Nuo and Nord reduce their sales growth and profit expectations for 2025.

Novo Nordisk warned on Tuesday that full-year sales and operating profit growth would be lower than previously expected, marking the second time the company has lowered its 2025 expectations. As the manufacturer of the weight loss drug Wegovy, Novo Nordisk is working hard to convince investors that it can still compete with its American rival Lilly in the weight loss drug frenzy. Over the past year, Novo's stock price has plummeted. The company said in a statement, "The downgrade in 2025 sales outlook is due to a lowered growth expectation for the second half of 2025." In local currency terms, Novo Nordisk currently expects sales in 2025 to grow by 8%-14%, lower than the previous expectation of 13%-21%. The company also lowered its operating profit growth forecast from 16%-24% to 10%-16%.